-
Neuroimage: The effect of acute inflammation on a person's visual attention.
Time of Update: 2020-10-12
current study uses electro-encephalograms (EEGs) to assess how inflammation affects three different attention processes: alertness, orientation, and executive control.
analysis focuses on the performance of behavioral tasks, as well as the modulation of oscillating electro-encephalogram activity in the α-band (9-12 Hz) for alertness and execution control of directional attention and the prelength band (4-8 Hz).
-
Clin Exp Rheumatol: Intravenous VS oral cyclophosphamide to treat the effects of systemic sclerosis on the lungs and/or skin fibrosis.
Time of Update: 2020-10-12
In placebo-controlled randomized clinical trials and observational studies, both intravenous (IV) and oral (PO) cyclophosphamide (CYC) have shown beneficial effects on skin and lungs of systemic sclerosis (SSc).
analyze severity (SAEs) and non-critical adverse events and efficacy data (FVC, DLCO, mRSS changes) at the end of CYC therapy (EoT) and follow-up (FU).
-
The FDA and EMA have accepted marketing applications for bimekizumab for the treatment of psoriasis.
Time of Update: 2020-10-11
"After a series of positive Phase III data, we are pleased to announce that the FDA and EMA have accepted our application to use bimekizumab as a potential new treatment for psoriasis," said Emmanuel Caeymaex, executive vice president of UMB at UCB.
-
Rheumatology: Risk of severe infection in patients with rheumatoid arthritis who receive JAK inhibitors.
Time of Update: 2020-10-11
This systematic literature review and meta-analysis is designed to assess the risk of severe infection (SI) and shingles (HZ) in patients with rheumatoid arthritis receiving JAK inhibitors, the results of which are published online in Rheaology.
-
Lilly says the new coronavirus combination therapy with antibodies is the main endpoint.
Time of Update: 2020-10-10
On October 8th Regency announced that its global partner, Eli Lilly and Company, had released positive in-period data for the treatment of newly diagnosed patients with mild and moderate coronary pneumonia (COVID-19) in combination with antibodies JS016 (LY-CoV016) and LY-CoV555.
-
Nat Immunol: A serious viral infection may "overwhelm" the body's immune cells.
Time of Update: 2020-10-07
September 16, 2020 // -- In a recent study published in the international journal Nature Immunology, scientists from the University of Melbourne and other institutions identified a special mechanism t
-
Reducing patient hospitalization Lilly announces preliminary clinical trial results for new coronal and antibody.
Time of Update: 2020-10-07
Today, Eli Lily and Company announced the concept validation data obtained in the mid-term analysis of the BLAZE-1 clinical trial of the new coronavirus and antibody LY-CoV555, developed jointly with AbCellera.
-
Cell: For the first time in the world, the battle between the puff macrophages and bacteria is revealed in real time.
Time of Update: 2020-10-07
September 16, 2020 /--- In a new study, researchers from the University of Calgary in Canada have discovered how to capture "live" images of immune cells in the lungs.
Cell, 2020, doi:10.1016/j.cell.2020.08.020.2.Researchers discover how to capture images of cells work at inside our lungs.
-
Anti-inflammatory drugs may shorten the recovery time of COVID19 patients.
Time of Update: 2020-10-07
September 16, 2020 /--- -- Lilly Pharmaceuticals Inc. said it will shorten its recovery time by adding anti-inflammatory drugs to drugs in hospitalized COVID-19 patients.
study participants were treated with remdesivir, a drug previously shown to shorten recovery time.
-
Science: The cGAS suppression mechanism that structurally reveals the dependence of nuclear small bodies.
Time of Update: 2020-10-07
September 16, 2020 /--- In a new study, researchers at the University of North Carolina at Chapel Hill identified for the first time a high-resolution structure in the innate immune system in which a key DNA-sensing protein called cGAS binds to a nucleus, the most important UNIT of DNA packaging in the nucleus.
-
Nat Med: Monoclonal antibody therapy may be expected to help treat COVID-19.
Time of Update: 2020-10-07
paper, researchers reveal how they used this fast-track antibody discovery platform to isolate hundreds of human monoclonal antibodies that protect against surface prick proteins (S) that promote SARS-CoV-2 infections in lung cells.
-
Nat Cancer: New immunotherapy is effective in treating cancer.
Time of Update: 2020-10-07
.com Source: Novel immune-oncology approach for potential cancer treatment Original source: A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response, Nature Cancer (2020).
-
Nat Cell Biol: Editing the immune response using CRISPR makes gene therapy more effective.
Time of Update: 2020-10-07
the main goal of this study is to develop CRISPR-based tools to treat inflammatory diseases," said Farzaneh Moghadam, ph.D. student at Kiani Labs and lead author of the paper.
-
JAAD: Immunosuppressive drugs do not increase the risk of COVID19 infection.
Time of Update: 2020-10-07
the main findings of their analysis: 36 percent of the 213 patients tested positive for COVID-19, and were more likely to be hospitalized or use a ventilator than the general population.
-
New drug for secondary immunodeficiency (SID)! Takeda HyQiva has been approved by the European Union to update the label: for adults, adolescents, children!
Time of Update: 2020-10-07
September 16, 2020 // -- Takeda recently announced that the European Commission (EC) has approved The HyQvia (Human Normal Immunoglobulin (10%), Recombinant Human Hyalurase) label update to expand its use, making it the first and only easy-to-use subsurface immunoglobulin replacement therapy for the treatment of a wider group of patients with secondary immunodeficiency (SID), including adults, adolescents and children.
-
eLife: A "hierarchy" of breast cancer cells or a potential cause of patient therapy tolerance.
Time of Update: 2020-10-07
Photo Source: USC Norris Comprehensive Cancer Center researcher Syn Yeo says the findings underscore the need and importance of explaining the presence of specific cell states in tumors, which may help identify specific combinations of drugs to eliminate all cell states, effectively suppressing or preventing cancer cells from developing certain tolerances to therapy.
-
Nature Sub-Journal: Revealing new mechanisms for coronavirus to intercept host cells to make viruses is expected to help develop new therapies and vaccines.
Time of Update: 2020-10-07
September 16, 2020 // -- In a recent study published in the international journal Nature Structural and Molecular Biology, scientists from the Federal Institute of Technology in Zurich and others reve
-
Innovative drug for eosinophilic esophitis! FDA Grants Sanofi/Regenerative Dupixent Breakthrough Drug Qualification: Phase III Clinical Efficacy Significant!
Time of Update: 2020-10-07
!-- Webeditor: page title -- Sanofi and partner Regeneron recently jointly announced that the U.S. Food and Drug Administration (FDA) has Awarded the breakthrough drug qualification (BTD) for the new anti-inflammatory drug Dupixent (Chinese commodity name: Dabito, generic name: Dupilumab) for the treatment of patients with 12-year-old eosinophilic esophitis (EoE).
-
Sci Immunol: Special immune molecular signals may promote the host body's antibody-dependent cytotoxic response to herpes simplex virus.
Time of Update: 2020-10-07
Natural infections in the body mainly cause the production of neutral antibodies targeting gD, but sub-unit protein vaccines designed to induce this reaction have now failed in clinical development; The researchers conducted these studies to test the hypothesis that gD interferes with ADCC through the involvement of HVEM, compared to wild controlled mice, by mediating the cytototoxic effects of antibody dependence (ADCC) by activating the expression of Fc gamma subjects (Fc-Rs).
-
How does PNAS hormone affect the risk of disease?
Time of Update: 2020-10-07
" Although biosteroids and adult sex hormones are known to have a significant impact on immune diseases between men and women, we understand that the hormones we come into contact with in the womb may play a greater role in determining the gender differences associated with fat cells.
